Incidence of antiphospholipid antibodies in new patients with non-Hodgkin lymphoma
Keywords:
non-Hodgkin’s lymphoma, antiphospholipid antibodies, incidenceAbstract
Non-Hodgkin’s lymphoma (NHL) presents a group of histologically and biologically inhomogeneous B and T cell neoplasms of lymphoid tissue with a completely unidentifi ed etiology. Antiphospholipid antibodies (aPL) are antibodies produced as a result of misinterpretation of platelet membrane phospholipids. It is well known that antiphospholipid antibodies are general risk factors that induce the disorder of the physiological process of hemostasis. Respectively, it is interesting to appreciate the incidence of antiphospholipid antibodies in new non-Hodgkin lymphomas patients depending on age, sex, type of non-Hodgkin’s lymphoma, the peculiarities of the onset of the disease, the degree of disease spread. According to the results of our study, we found a 14.8% incidence of aPL in primary patients with non-Hodgkin’s lymphoma, more frequently in men and people older than 50 years. The positivity of aPL antibodies depended on the immunohistochemical type of malignant lymphoma, the degree of dissemination of the tumor process and independent of the location of the tumor focus (nodal or extranodal) of NHL. The incidence of aPL antibody types was uneven with the obvious predominance of lupus anticoagulant. Th is study allowed the evaluation of the incidence of antiphospholipid antibodies in primary patients with non-Hodgkin’s lymphoma
References
1. Хансон К.П., Имянитов Е.Н. Эпидемиология и биология неходжкенских лимфом. В: Практическая онкология. 2004, №. 5, том 3, стр. 163-168.
2. Solomon J., Arcila M. Molecular Diagnostics of NonHodgkin Lymphoma. In: The Cancer Journal. 2020, nr. 26, vol. 3, pp. 186-194. https://doi.org/10.1097/PPO.0000000000000447
3. Ikeda S., Koga S., Yamagata Y. et.al. Comparision of the eff ects of endoxaban an oral direct factor Xa inhibitor on venous thromboembolism between patients with and without cancer. In: Journal Cardiology. 2018, nr. 72, pp. 120-127. https://doi.org/10.1016/j.jjcc.2018.03.006
4. Buruiana S. Managementul riscului complicațiilor trombembolice în oncologie. În: Sănătate Publică, Economie și Management în Medicină. 2021, nr. 1, vol. 88, pp. 57-62.
5. Murillo C., Ordoñez K., Figueroa E. et. al. Venous Thromboembolism (VTE) in Adults with Non-Hodgkin Lymphoma (NHL) a Retrospective Cohort Study. In: Blood. 2017, nr. 130 (Supplement 1), pp. 4906. https://doi.org/10.1182/blood.V130.Suppl_1.221.677
6. Фёдоров А., Дмитриев В., Липай Н. Венозные тромбозы у детей, подростков и молодых взрослых больных лимфомами: частота развития, характеристика, факторы риска и влияние на прогноз. В: Онкогематология. 2018, №. 2, том 13, стр. 9-21.
7. Липай Н., Фёдоров А., Дмитриев В. Тромботические осложнения у детей с неходжкенскими лимфомами. В: Онкогематология. 2013, №. 2, стр. 41-46.
8. Tкаченко О.Ю., Лапин С.В., Шмонин А.А., и др. Анализ спектра антифосфолипидных антител у пациентов с тромбозами и привычным невынашиванием беременности. В: Медицинская иммунология. 2018, № 20, том 5, стp. 753-762.
9. Решетняк Т.М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). В: Научно-практическая ревматология. 2014, № 52, том 1, стр. 56-71.
10. Волкова М.В., Кундер Е.В., Генералов И.И., Роггенбук Д. Анти- фосфолипидные антитела: современные представления о патогенетическом дей ствии и лабораторной диагностике. В: Вестник Витебского государственного медицинского университета. 2015, №14, том 3, стp. 6-15.
11. Manukyan D., Rossmann H., Schulz A., Zeller T., Pfeiff er N., Binder H. et al. Distribution of antiphospholipid antibodies in a large population-based German cohort. In: Clin Chem Lab Med. 2016, nr. 54, pp. 1663-70. https://doi.org/10.1515/cclm-2016-0014
12.Kungwankiattichai S, Nakkinkun Y, Owattanapanich W, Ruchutrakool T. High Incidence of Antiphospholipid Antibodies in Newly Diagnosed Patients With Lymphoma and a Proposed aPL Predictive Score. In: Clin Appl Thromb Hemost. 2020;26:1076029620928392. https://doi.org/10.1177/1076029620928392
13. Kunawuttinankorn W., Tanyasalnsook K., Rojnuckarin P. Incidence and risk factors for venous thromboembolism Thai hospitalized lymphoma patients. In: Pharm. Sci. Asia. 2018, nr. 45, vol. 2, pp. 114-122. https://doi.org/10.29090/psa.2018.02.114
14. Musial J. Antiphospholipid antibodies and thrombosis. In: Thromb Res. 2012, nr. 129, vol. 3, pp. 345-7. https://doi.org/10.1016/j.thromres.2011.10.029
15. Buruiana S., Mazur M., Robu M. et al. The frequency of Anticardiolipin Antibodies in Patients with NonHodgkin Lymphoma. In: Clinical Lymphoma, Myeloma & Leukemia. 2020, nr. 20, vol. 1, p. 282. https://doi.org/10.1016/S2152-2650(20)30905-8
16. Wu M., Barnard J., Kundu S., McCrae K.R. A novel pathway of cellular activation mediated by antiphospholipid antibody-induced extracellular vesicles. In: J Thromb Haemost. 2015, nr. 13, vol. 10, pp. 1928-40. https://doi.org/10.1111/jth.13072
17. Muller-Calleja N., Lackner K.J. Mechanisms of cellular activation in the antiphospholipid syndrome. In: Semin Thromb Hemost. 2018, nr. 44, vol. 5, pp. 483-92. https://doi.org/10.1055/s-0036-1597290
18. Pierangeli S.S., Vega-Ostertag M.E., Raschi E. et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo. In: Ann Rheum Dis. 2007, nr. 66, vol. 10, pp. 1327-33. https://doi.org/10.1136/ard.2006.065037
19. Charfurvedi S., Mc Crae K. The antiphospholipide syndrome:still an enigma. In: Hematology Am Soc Hematol Educ Program. 2015, nr. 1, pp. 53-60. 20. Дмитриев В.В., Федорова А.С., Липай Н.В., и др. Свертывание крови и антикоагулянтная терапия при венозных тромбозах, осложнивших лечение детей, подростков и молодых взрослых с лимфомами. В: Онкогематология. 2018, № 4, том 13, стp. 37-45.
21. Payandeh M., Sadeghi M., Sadeghi E. Advances in nonHodgkin's lymphoma. In: American Journal of Cancer Prevention. 2015, nr. 3, vol. 5.
22. Lund J., Ostgard L., Prandoni P. Incidence, determinants and the transient impact of cancer treatments on venous thrombembolism risk among lymphoma patients in Denmark. In: Thrombosis Research. 2015, nr. 136, pp. 917-923. https://doi.org/10.1016/j.thromres.2015.09.001
23. Sanfi lippo K. Incidence of venous thrombembolism in patients with non-Hodgkin lymphoma. In: Thrombosis Research. 2016, nr. 143, pp. 86-90. https://doi.org/10.1016/j.thromres.2016.05.008
24. Ionescu R. Antiphospholipid syndrome and cancer. Romanian Journal of Rheumatology. 2021, nr. 30, vol. 1. doi: 10.37897/RJR.2021.1.2. https://doi.org/10.37897/RJR.2021.1.2
25. Islam A., Tayar JH, Fa'ak F. et al. Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. In: Blood Advanse. 2020, nr. 4, vol. 8, pp. 1746-1755. https://doi.org/10.1182/bloodadvances.2020003350
26. Buruiana S., Robu M., Mazur-Nicorici L. ș.a. Prevalența anticorpilor anticardiolipinici la pacienții cu limfom Non-Hodgkin. In: Buletinul Academiei de Științe a Moldovei. Științe medicale. 2020, nr. 2, vol. 66, pp. 114-117.
27. Chan T., Hwang Y., Tse E. Risk assessment of venous thromboembolism in hematological cancer patients: a review.In: Expert Review of Hematology. 2020, nr. 13, vol. 5, pp. 471-480. https://doi.org/10.1080/17474086.2020.1751608
28. Pusterla S., Previtali S., Marziali S. et. al. Antiphospholipid antibodies in lymphoma: Prevalence and clinical signifi cance. In: The Hematology Journal. 2004, nr. 5, vol. 4, pp. 341-6. https://doi.org/10.1038/sj.thj.6200377
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
